NeuroSearch TIPOs the scales

NeuroSearch A/S believes its tesofensine obesity therapeutic may provide greater efficacy than marketed drugs due to its long half-life and mechanism of action that involves inhibiting the reuptake of three monoamines - serotonin, dopamine and norepinephrine. Last week’s interim results from the TIPO-4 extension of the 24-week Phase IIb TIPO-1 trial bolster the company’s case, as it now has data showing tesofensine’s effects persist for at least an additional 24 weeks.

TIPO-1 was a double-blind trial in which 203 patients received 0.25, 0.5 or 1 mg doses of tesofensine or placebo. The average weight loss at 24 weeks in the low, medium and high-dose groups was 6.7, 11.3 and 12.8 kg vs. a loss of 2.2 kg for placebo (p<0.0001 for all)...